ArticleCureus2026
Chilling Complications: A Case of Cryoglobulinemic Vasculitis in a Patient With Newly Diagnosed Sjögren's Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In rare circumstances, Sjögren's syndrome can cause systemic illness in the form of cryoglobulinemic vasculitis (CV). Diagnostic workup is of the utmost importance to prevent severe end-organ damage and even death, especially in the case of rapidly progressive disease. In this case, a 47-year-old male presented to the hospital with shortness of breath, unilateral leg swelling, and a lower extremity wound worsening over a three-month period. During this admission, the patient was found to have diffuse lymphadenopathy with a negative workup for malignancy. The patient met the criteria for Sjögren's syndrome and was initiated on outpatient disease-modifying antirheumatic drug (DMARD) therapy. The patient was readmitted to the hospital in undifferentiated shock and was found to have CV, with significant end-organ damage. He was treated with pulse-dose steroids, plasmapheresis, and rituximab infusions. After a lengthy three-month admission, he was finally discharged in stable condition. CV can present very similarly to antiphospholipid syndrome and antineutrophil cytoplasmic antibody (ANCA) vasculitis. Biopsies prove invaluable in the diagnosis. This manifestation of Sjögren's syndrome is uncommon, and it is often difficult to assess which patients may be more at risk for the complication. This case illustrates the importance of early identification of patients with Sjögren's syndrome who may be at risk for the development of vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.